Search Results - "William R. Lenderking"

Vocal Acoustic Biomarkers of Depression Severity and Treatment Response by Mundt, James C, Vogel, Adam P, Feltner, Douglas E, Lenderking, William R

“…Background Valid, reliable biomarkers of depression severity and treatment response would provide new targets for clinical research. Noticeable differences in…”
Get full text

ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research by Reeve, Bryce B., Wyrwich, Kathleen W., Wu, Albert W., Velikova, Galina, Terwee, Caroline B., Snyder, Claire F., Schwartz, Carolyn, Revicki, Dennis A., Moinpour, Carol M., McLeod, Lori D., Lyons, Jessica C., Lenderking, William R., Hinds, Pamela S., Hays, Ron D., Greenhalgh, Joanne, Gershon, Richard, Feeny, David, Fayers, Peter M., Cella, David, Brundage, Michael, Ahmed, Sara, Aaronson, Neil K., Butt, Zeeshan

“…Purpose An essential aspect of patient-centered outcomes research (PCOR) and comparative effectiveness research (CER) is the integration of patient…”
Get full text

Recommendations on Evidence Needed to Support Measurement Equivalence between Electronic and Paper-Based Patient-Reported Outcome (PRO) Measures: ISPOR ePRO Good Research Practices Task Force Report by Coons, Stephen Joel, PhD, Gwaltney, Chad J., PhD, Hays, Ron D., PhD, Lundy, J. Jason, PhD, Sloan, Jeff A., PhD, Revicki, Dennis A., PhD, Lenderking, William R., PhD, Cella, David, PhD, Basch, Ethan, MD, MSc

“…Abstract Background Patient-reported outcomes (PROs) are the consequences of disease and/or its treatment as reported by the patient. The importance of PRO…”
Get full text

The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey by Tandon, Rajiv, Lenderking, William R, Weiss, Catherine, Shalhoub, Huda, Barbosa, Carla Dias, Chen, Jun, Greene, Mallik, Meehan, Stine R, Duvold, Laëtitia Bouérat, Arango, Celso, Agid, Ofer, Castle, David

“…It is well established that the different antipsychotics used for schizophrenia symptoms differ substantially in their side effects. However, relatively little…”
Get full text

Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers by Stewart, Michelle, Shaffer, Shannon, Murphy, Brian, Loftus, Jane, Alvir, Jose, Cicchetti, Michael, Lenderking, William R.

“…Introduction Transthyretin amyloidosis (ATTR amyloidosis), whether manifesting as familial amyloid polyneuropathy (ATTR-PN) or cardiomyopathy (ATTR-CM), is a…”
Get full text

Qualitative evaluation of the Autism Behavior Inventory: use of cognitive interviewing to establish validity of a caregiver report scale for autism spectrum disorder by Pandina, Gahan, Ness, Seth, Trudeau, Jeremiah, Stringer, Sonja, Knoble, Naomi, Lenderking, William R, Bangerter, Abigail

“…The Autism Behavior Inventory (ABI) is an observer-reported outcome scale measuring core and associated features of autism spectrum disorder (ASD). Extensive…”
Get full text

Responsiveness and minimal important differences for patient reported outcomes by Revicki, Dennis A, Cella, David, Hays, Ron D, Sloan, Jeff A, Lenderking, William R, Aaronson, Neil K

“…Patient reported outcomes provide the patient's perspective on the effectiveness of treatment. The draft Food and Drug Administration guidance on patient…”
Get full text

Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO by Younossi, Zobair M., Afendy, Arian, Stepanova, Maria, Racila, Andrei, Nader, Fatema, Gomel, Rachel, Safer, Ricky, Lenderking, William R., Skalicky, Anne, Kleinman, Leah, Myers, Robert P., Subramanian, G. Mani, McHutchison, John G., Levy, Cynthia, Bowlus, Christopher L., Kowdley, Kris, Muir, Andrew J.

“…Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with inflammation and biliary fibrosis that leads to cholangitis, cirrhosis, and…”
Get full text

Impact of trazodone once‐a‐day on quality of life and functional recovery in adults with major depressive disorder: A prospective, observational study by Tellone, Valeria, Markovic, Oto, Strashimirova, Milena, Sani, Gabriele, Lenderking, William R., Margolis, Mary Kay, Fallone, Raffaella, Quarchioni, Elisa, Cattaneo, Agnese, Comandini, Alessandro

“…Background Health‐related quality of life (HRQL) is an important goal for patients with major depressive disorder (MDD), but whether antidepressants improve…”
Get full text

Identifying symptomatic adverse events using the patient‐reported outcomes version of the common terminology criteria for adverse events in patients with non‐small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations by Zhu, Yanyan, Jean‐Baptiste, Milenka, Lenderking, William R., Bell, Jill A., Revicki, Dennis A., Lin, Huamao M., Brake, Rachael, Reeve, Bryce B.

“…Objective Tolerability and safety of treatments are important in oncology trials and should be informed by patient assessments. We identified the most relevant…”
Get full text

Psychometric evaluation of the patient-reported experience of cognitive impairment in schizophrenia (PRECIS) scale by Lenderking, William R., Atkinson, Mark J., Ladd, Mary Kate, Savva, Yulia, Sommer, Stephanie, Sidovar, Matthew, Hastedt, Claudia

“…Background Cognitive impairment associated with schizophrenia (CIAS) represents a distinct, persistent, and core group of schizophrenia symptoms. Cognitive…”
Get full text

Measuring health-related quality of life in patients with rare disease by Lenderking, William R., Anatchkova, Milena, Pokrzywinski, Robin, Skalicky, Anne, Martin, Mona L., Gelhorn, Heather

“…Background There has been a growing emphasis on health-related quality of life (HRQoL) as an important outcome in rare disease drug development, although its…”
Get full text

Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb) by Seng, Elizabeth, Lampl, Christian, Viktrup, Lars, Lenderking, William R., Karn, Hayley, Hoyt, Margaret, Kim, Gilwan, Ruff, Dustin, Ossipov, Michael H., Vincent, Maurice

“…Introduction Migraine is under-diagnosed and under-treated. Many people with migraine do not seek medical care, and those who do may initially receive a…”
Get full text

Re-examining the factor structure of the Insomnia Severity Index (ISI) and defining the meaningful within-individual change (MWIC) for subjects with insomnia disorder in two phase III clinical trials of the efficacy of lemborexant by Lenderking, William R., Savva, Yulia, Atkinson, Mark J., Campbell, Renee, Chabot, Isabelle, Moline, Margaret, Meier, Genevieve, Morin, Charles M.

“…Background The Insomnia Severity Index (ISI) is a widely used measure of insomnia severity. Various ISI research findings suggest different factor solutions…”
Get full text

Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration by Marshall, Randall D, Collins, Abigail, Escolar, Maria L, Jinnah, H A, Klopstock, Thomas, Kruer, Michael C, Videnovic, Aleksandar, Robichaux-Viehoever, Amy, Burns, Colleen, Swett, Laura L, Revicki, Dennis A, Bender, Randall H, Lenderking, William R

“…Pantothenate kinase-associated neurodegeneration (PKAN) is an autosomal recessive neurodegenerative disorder with brain iron accumulation (NBIA). To assess…”
Get full text

Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis by Cella, David, Lenderking, William R., Chongpinitchai, Peter, Bushmakin, Andrew G., Dina, Oluwaseyi, Wang, Lisy, Cappelleri, Joseph C., Navarro-Compán, Victoria

“…Background The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale has demonstrated good internal consistency and responsiveness to…”
Get full text

Symptom burden and health-related quality of life impacts of smoldering multiple myeloma: the patient perspective by Jean-Baptiste, Milenka, Gries, Katharine S., Lenderking, William R., Fastenau, John

“…Background Smoldering multiple myeloma (SMM) is an early form of multiple myeloma (MM). SMM is typically considered asymptomatic, and research on how it…”
Get full text

Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study by Tanner, Caroline M., Caroff, Stanley N., Cutler, Andrew J., Lenderking, William R., Shalhoub, Huda, Pagé, Véronique, Franey, Ericha G., Serbin, Michael, Yonan, Chuck

“…Abstract Background Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with antipsychotic use. Data from…”
Get full text

Correction to: The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey by Tandon, Rajiv, Lenderking, William R, Weiss, Catherine, Shalhoub, Huda, Barbosa, Carla Dias, Chen, Jun, Greene, Mallik, Meehan, Stine R, Duvold, Laëtitia Bouérat, Arango, Celso, Agid, Ofer, Castle, David

“…[This corrects the article DOI: 10.1186/s12991-020-00292-5.]…”
Get full text

Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events by Speck, Rebecca M., Lenderking, William R., Shaw, James W.

“…Background Incorporating patient reporting of symptomatic adverse events (AEs) is important in evaluating safety and tolerability in cancer clinical trials…”
Get full text